ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Addex Therapeutics Ltd.
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 20-F on May 15, 2026
$2.89+0.13 (+4.71%)
Close on Oct 19, 2026
Share price
−$8.06 (−73.61%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Addex Therapeutics Ltd. saw revenue fall 74.9% to CHF 404.10K over fiscal 2024. Free cash flow was -CHF 5.37M.
Revenue
CHF 404.10K
-74.9% vs. a year earlier
Operating income
-CHF 2.76M
FY2024
Free cash flow
-CHF 5.37M
FY2024
EPS, diluted
0.07 CHF
FY2024
Key statistics
Valuation at the latest close; fundamentals over fiscal 2024, balances at Jun 30, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- CHF 404.10K
- EPS, diluted
- 0.07 CHF
- Free cash flow
- -CHF 5.37M
- Diluted shares
- 101M
Valuation needs the share price. It fills in once daily prices are connected and converted from CHF.
Nine years at a glance
Fiscal years 2016 to 2024, CHF
Revenue
CHF 404.10K-74.9% YoY
Operating income
-CHF 2.76M
EPS, diluted
0.07 CHF
Free cash flow
-CHF 5.37M
Reported period